Cell therapy https://www.bioworld.com/rss en-us Scientists rehabilitate disease-causing T cells into tolerance builders BioWorld. “They can’t distinguish good immune cells and bad immune cells,” which is why many carry black-box warnings and must be taken for years, sometimes for life.]]> http://www.bioworld.com/articles/725901 Tue, 04 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725901-scientists-rehabilitate-disease-causing-t-cells-into-tolerance-builders T cells Scientists rehabilitate disease-causing T cells into tolerance builders BioWorld. “They can’t distinguish good immune cells and bad immune cells,” which is why many carry black-box warnings and must be taken for years, sometimes for life.]]> http://www.bioworld.com/articles/725752 Mon, 03 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725752-scientists-rehabilitate-disease-causing-t-cells-into-tolerance-builders T cells Astellas-Yaskawa JV to build robot-based cell production platform http://www.bioworld.com/articles/718192 Tue, 11 Mar 2025 11:00:00 -0400 https://www.bioworld.com/articles/718192-astellas-yaskawa-jv-to-build-robot-based-cell-production-platform Astellas Yaskawa Maholo Astellas Yaskawa Maholo. Credit: Astellas, Yaskawa Astellas-Yaskawa JV to build robot-based cell production platform http://www.bioworld.com/articles/717733 Thu, 06 Mar 2025 11:00:00 -0500 https://www.bioworld.com/articles/717733-astellas-yaskawa-jv-to-build-robot-based-cell-production-platform Astellas Yaskawa Maholo Astellas Yaskawa Maholo. Credit: Astellas, Yaskawa For the 99%, allografts can patch up failing heart http://www.bioworld.com/articles/716972 Fri, 31 Jan 2025 09:00:00 -0500 https://www.bioworld.com/articles/716972-for-the-99-allografts-can-patch-up-failing-heart Heart patch produced from induced pluripotent stem cells derived heart muscle cells in a collagen hydrogel The heart patch is produced from induced pluripotent stem cells derived from heart muscle cells in a collagen hydrogel. Credit: University Medical Center Göttingen/ Eva Meyer-Besting For the 99%, allografts can patch up failing heart http://www.bioworld.com/articles/716887 Thu, 30 Jan 2025 09:00:00 -0500 https://www.bioworld.com/articles/716887-for-the-99-allografts-can-patch-up-failing-heart Heart patch produced from induced pluripotent stem cells derived heart muscle cells in a collagen hydrogel The heart patch is produced from induced pluripotent stem cells derived from heart muscle cells in a collagen hydrogel. Credit: University Medical Center Göttingen/ Eva Meyer-Besting For the 99%, allografts can patch up failing heart http://www.bioworld.com/articles/716733 Wed, 29 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716733-for-the-99-allografts-can-patch-up-failing-heart Heart patch produced from induced pluripotent stem cells derived heart muscle cells in a collagen hydrogel The heart patch is produced from induced pluripotent stem cells derived from heart muscle cells in a collagen hydrogel. Credit: University Medical Center Göttingen/ Eva Meyer-Besting MD Anderson announces new Institute for Cell Therapy Discovery & Innovation http://www.bioworld.com/articles/714322 Mon, 11 Nov 2024 09:00:00 -0500 https://www.bioworld.com/articles/714322-md-anderson-announces-new-institute-for-cell-therapy-discovery-and-innovation Natural killer cell attacking cancer cell Triumvira’s TAC01-CLDN18.2 T-cell therapy outperforms CAR T strategies http://www.bioworld.com/articles/713571 Fri, 18 Oct 2024 09:00:00 -0400 https://www.bioworld.com/articles/713571-triumviras-tac01-cldn182-t-cell-therapy-outperforms-car-t-strategies Kytopen receives phase II SBIR grant http://www.bioworld.com/articles/711548 Fri, 16 Aug 2024 09:00:00 -0400 https://www.bioworld.com/articles/711548-kytopen-receives-phase-ii-sbir-grant Human natural killer cell Colorized scanning electron micrograph of a natural killer cell from a human donor. Credit: NIAID Abata gets equity investment from Bristol Myers Squibb http://www.bioworld.com/articles/711547 Fri, 16 Aug 2024 09:00:00 -0400 https://www.bioworld.com/articles/711547-abata-gets-equity-investment-from-bristol-myers-squibb Treg cells ROBO1 CAR T cells fight tumors and metastases in brain http://www.bioworld.com/articles/711289 Wed, 07 Aug 2024 09:00:00 -0400 https://www.bioworld.com/articles/711289-robo1-car-t-cells-fight-tumors-and-metastases-in-brain CAR T cells attacking cancer cell Cellatoz’s CLZ-2002 restores nerve myelination in preclinical Charcot-Marie-Tooth disease http://www.bioworld.com/articles/708684 Wed, 22 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708684-cellatozs-clz-2002-restores-nerve-myelination-in-preclinical-charcot-marie-tooth-disease Nervous system illustration FT-522 CAR NK therapy shows dual targeting cytotoxicity, persistence in systemic autoimmunity models http://www.bioworld.com/articles/708632 Fri, 17 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708632-ft-522-car-nk-therapy-shows-dual-targeting-cytotoxicity-persistence-in-systemic-autoimmunity-models Human natural killer cell Colorized scanning electron micrograph of a natural killer cell from a human donor. Credit: NIAID Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems http://www.bioworld.com/articles/708533 Thu, 16 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708533-grant-supports-lift-biosciences-evaluation-of-iman-cell-therapies-in-humanized-in-vivo-model-systems 3D illustration of tumor CD19-specific KIR-CAR T-cell therapy shows efficacy in models of B-cell malignancies http://www.bioworld.com/articles/708447 Mon, 13 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708447-cd19-specific-kir-car-t-cell-therapy-shows-efficacy-in-models-of-b-cell-malignancies HRYZ-T102, mutated AFP-specific TCR engineered T-cell therapy with improved functionality http://www.bioworld.com/articles/708343 Wed, 08 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708343-hryz-t102-mutated-afp-specific-tcr-engineered-t-cell-therapy-with-improved-functionality T cells attacking cancer cells IND for Syena’s SY-307 cleared by FDA http://www.bioworld.com/articles/708047 Tue, 30 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/708047-ind-for-syenas-sy-307-cleared-by-fda Natural killer cell attacking cancer cell Tr1x’s TRX-103 to enter phase I following IND clearance http://www.bioworld.com/articles/707396 Thu, 11 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707396-tr1xs-trx-103-to-enter-phase-i-following-ind-clearance Stem cells GC Cell reports data on anti-CD5 CAR-NK therapy with potent efficacy, long-term in vivo persistence in blood http://www.bioworld.com/articles/707392 Thu, 11 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707392-gc-cell-reports-data-on-anti-cd5-car-nk-therapy-with-potent-efficacy-long-term-in-vivo-persistence-in-blood HIP-engineered islet graft achieves insulin independence without immunosuppression in NHP model http://www.bioworld.com/articles/705609 Fri, 16 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705609-hip-engineered-islet-graft-achieves-insulin-independence-without-immunosuppression-in-nhp-model Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo http://www.bioworld.com/articles/705575 Wed, 14 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705575-autologous-b-cell-therapy-wfx-001-corrects-systemic-gal-enzyme-deficiency-in-vivo Medigene selects clinical indications for TCR-T therapy http://www.bioworld.com/articles/705538 Tue, 13 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705538-medigene-selects-clinical-indications-for-tcr-t-therapy Illustration of cancer cells and immunotherapy treatment Acepodia’s allogeneic γδ2 T-cell therapy for EGFR-expressing solid tumors cleared to enter clinic http://www.bioworld.com/articles/705316 Mon, 05 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705316-acepodias-allogeneic-2-t-cell-therapy-for-egfr-expressing-solid-tumors-cleared-to-enter-clinic 3D illustration of T cells fighting cancer Combining AMP vaccination with TCR T-cell therapies leads to improved and durable antitumor efficacy http://www.bioworld.com/articles/705192 Thu, 01 Feb 2024 09:00:00 -0500 https://www.bioworld.com/articles/705192-combining-amp-vaccination-with-tcr-t-cell-therapies-leads-to-improved-and-durable-antitumor-efficacy Bluerock exercises option to primary photoreceptor diseases iPSC http://www.bioworld.com/articles/705027 Fri, 26 Jan 2024 09:00:00 -0500 https://www.bioworld.com/articles/705027-bluerock-exercises-option-to-primary-photoreceptor-diseases-ipsc Close-up of eye with digital focus NK Celltech announces US IND clearance for NK cell therapy NK-010 http://www.bioworld.com/articles/704863 Tue, 23 Jan 2024 09:00:00 -0500 https://www.bioworld.com/articles/704863-nk-celltech-announces-us-ind-clearance-for-nk-cell-therapy-nk-010 3d illustration of ovarian cancer Tr1x series A to advance allogeneic cell therapies http://www.bioworld.com/articles/704757 Thu, 18 Jan 2024 09:00:00 -0500 https://www.bioworld.com/articles/704757-tr1x-series-a-to-advance-allogeneic-cell-therapies DoD grant supports Factor Bioscience's development of gene-edited cell therapies http://www.bioworld.com/articles/704526 Fri, 12 Jan 2024 09:00:00 -0500 https://www.bioworld.com/articles/704526-dod-grant-supports-factor-biosciences-development-of-gene-edited-cell-therapies Gene editing illustration Iaso, Umoja collaborate on cell and gene therapies http://www.bioworld.com/articles/704321 Thu, 04 Jan 2024 09:00:55 -0500 https://www.bioworld.com/articles/704321-iaso-umoja-collaborate-on-cell-and-gene-therapies Handshake with DNA, molecules